Medovate signs exclusive agreement with Vygon to distribute regional anaesthesia device

16th October, 2020

Medovate, a dynamic medical device company dedicated to the development and commercialisation of innovative medical technologies, and Vygon Group, a group specialising in single-use medical devices, today announce that they have signed an exclusive deal to distribute SAFIRA® (SAFer Injection for Regional Anaesthesia) across 60 countries. Vygon will start a phased launch of SAFIRA in Europe at the end of 2020, with other global markets to follow.

Developed in collaboration with clinicians at the Queen Elizabeth Hospital King’s Lynn NHS Trust, SAFIRA transforms the technique of Peripheral Nerve Blockade into a one-person procedure, giving the anaesthetist full control of the injection at all times. This pioneering technology also improves patient safety by helping reduce the risk of nerve damage, as it prevents anaesthetic from being injected at high pressures. Furthermore, economic modelling has shown SAFIRA has the potential to help generate significant time and cost savings in a medical setting.

Amid the current COVID-19 pandemic, the European Society for Regional Anaesthesia (ESRA) has recommended that regional anaesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient. Regional anaesthesia preserves respiratory function and avoids aerosolization and the potential for transmission of COVID-19, compared to general anaesthesia. By making regional anaesthesia a one-person procedure SAFIRA helps hospitals meet these recent recommendations.

Vygon is one of the largest independent French medical device companies. It supplies more than 205 million products globally per year. A world-leader in the regional anaesthesia arena, it is perfectly placed to ensure SAFIRA – which recently attained EU CE regulatory approval – achieves its maximum reach and potential across Europe and beyond.

Medovate is a medtech company founded to assist Health Enterprise East and other NHS partners in commercialising essential new technologies created through a development pipeline of NHS innovations, with a focus on anaesthesia, airway, critical care and surgery.

“This agreement with Vygon marks a significant milestone in the launch of SAFIRA across Europe, the US and a number of other markets,” said Stuart Thomson, Managing Director, Medovate. “This will help establish Medovate on the world stage as a recognized medical device developer and manufacturer. In addition, it raises the international profile of the UK NHS and its clinicians, who are key stakeholders in Medovate and inventors of the SAFIRA innovation.”

“This is a very exciting partnership for Vygon,” said John Kerridge, Vice President, Anaesthesia & Emergency Business Unit, Vygon. “The SAFIRA technology, in terms of its impact on patient safety and clinical end-user efficiency, is in-line with our overall objective of patient/practitioner-based healthcare solutions. The fact that in the very near future the SAFIRA technology will be available in NRFit format further supports this objective. It will enable us to offer a complete NRFit solution for those markets that demand it.”

NRFit (trademark of GEDSA) devices provide dedicated connectors, compliant with ISO 80369-6. NRFit connectors aim to reduce the risk of wrong route administration of medications associated with Regional Anaesthesia procedures.

It is estimated that ten million regional anaesthesia procedures are performed across Europe every year. As the use of regional anaesthesia continues to grow steadily across Europe, SAFIRA has the potential to make a significant impact.

You can find out more about SAFIRA®, the clinicians behind it and HEE's role in commercialising the technology from our case study.

Keep up to date with all HEE news and events.

We take your data very seriously, please read our privacy policy.

Talk to us

We offer a free 30-minute consultation to explore how our team of experts can help you develop, commercialise and scale your medical technology.

Book Now